DEFM14A: Accolade to be Acquired by Transcarent for $7.03 Per Share in Cash

Accolade, Inc. has agreed to be acquired by Transcarent, Inc. for $7.03 per share in cash, representing a premium over the company's recent trading prices.

Summary

• Accolade, Inc. is set to be acquired by Transcarent, Inc. in a merger agreement dated January 8, 2025.
• Under the agreement, Merger Sub, a wholly-owned subsidiary of Transcarent, will merge into Accolade, with Accolade continuing as the surviving corporation.
• Accolade stockholders will receive $7.03 in cash per share, subject to applicable withholding taxes, unless they exercise appraisal rights.
• The per share price represents a premium of approximately 110% over the closing price on January 7, 2025, and approximately 98% over the 30-day volume weighted average price ending January 7, 2025.
• The Accolade Board recommends stockholders vote for the merger agreement, the compensation proposal, and the adjournment proposal.
• The special meeting for stockholders to vote on the proposal is scheduled for March 27, 2025.
• The merger requires approval by a majority of the outstanding shares as of the record date, February 18, 2025.
• The transaction is expected to close in the second quarter of calendar year 2025, pending regulatory approvals and satisfaction of other closing conditions.

Sentiment

Score: 7

Explanation: The document presents a balanced view of the merger, highlighting both the benefits and potential risks. The recommendation from the board is positive, but the document is factual and avoids overly promotional language.

Positives

• Stockholders will receive $7.03 per share in cash, providing immediate liquidity.
• The per share price represents a significant premium over recent trading prices.
• The Accolade Board has determined the merger is in the best interests of stockholders.
• Morgan Stanley rendered its oral opinion, which was subsequently confirmed in writing, to the Accolade Board to the effect that, as of that date, and based upon and subject to the assumptions made, procedures followed, matters considered and qualifications and limitations on the scope of the review undertaken by Morgan Stanley as set forth in Morgan Stanleys written opinion, the merger consideration to be received by the holders of shares of Common Stock (other than the Excluded Shares) was fair, from a financial point of view, to such holders of Common Stock.

Negatives

• Stockholders will no longer participate in any future earnings or growth of Accolade as an independent company.
• The merger is subject to regulatory approvals and other closing conditions, creating uncertainty.
• The merger agreement restricts Accolade's ability to solicit other acquisition proposals.
• If the merger is terminated under certain circumstances, Accolade may be required to pay Parent a termination fee of $19,800,000.

Risks

• The merger may not be completed if regulatory approvals are not obtained or other closing conditions are not met.
• The price of Accolade's shares may decline significantly if the merger is not completed.
• The merger agreement restricts Accolade's ability to pursue other strategic opportunities.
• There is a risk of litigation related to the merger.

Future Outlook

The merger is expected to close in the second quarter of calendar year 2025, subject to regulatory approvals and other customary closing conditions.

Management Comments

• The Accolade Board, after considering the factors more fully described in the section of this proxy statement captioned The MergerReasons for the Merger and upon the recommendation of the Special Committee (as defined below), (1) determined that the entry into the merger agreement and the consummation of the transactions contemplated by the merger agreement, including the merger, are advisable and fair to, and in the best interests of, Accolade and its stockholders; (2) authorized and approved the execution, delivery and performance by Accolade of the merger agreement and the consummation of the transactions contemplated by the merger agreement, including the merger; (3) recommended that Accolade stockholders adopt the merger agreement and approve the merger and the transactions contemplated by the merger agreement; and (4) directed that the merger agreement be submitted for consideration aby the Accolade stockholders at the special meeting.

Industry Context

The acquisition reflects ongoing consolidation trends in the healthcare technology sector, as companies seek to expand their capabilities and market reach.

Comparison to Industry Standards

• The proxy statement does not contain enough information to make a detailed comparison to industry standards.
• A more detailed analysis would require a review of the financial projections, the fairness opinion, and the specific terms of the merger agreement.
• Comparisons to other transactions in the healthcare technology sector would also be necessary to assess the fairness of the deal.

Legal Proceedings

• Following the announcement of the merger, a complaint was filed in the United States District Court for the Northern District of Illinois against Accolade and its directors captioned Venable v. Accolade Inc., et al., No. 1:25-cv-01506 (N.D. Ill.).
• The complaint asserts violations of Section 14(a) and Section 20(a) of the Securities Exchange Act of 1934, as amended, and alleges that the preliminary proxy statement filed in connection with the proposed transaction between Accolade and Parent omitted certain purportedly material information which rendered the preliminary proxy statement incomplete and misleading.
• The complaint seeks to enjoin Accolade from proceeding with or consummating the proposed transaction and seeks to recover damages in the event the proposed transaction is consummated.

Stakeholder Impact

• Stockholders will receive cash for their shares.
• Employees may experience changes in compensation and benefits.
• Customers and suppliers may be affected by the integration of Accolade into Transcarent.

Next Steps

• Stockholders to vote on the merger agreement, compensation proposal, and adjournment proposal at the special meeting on March 27, 2025.
• Accolade and Parent to obtain necessary regulatory approvals.
• Parent to secure financing for the transaction.
• If approved and all conditions are met, the merger will close in the second quarter of calendar year 2025.

Key Dates

Keywords

merger, acquisition, Transcarent, Accolade, stockholders, agreement, shares, proposal, cash, vote